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Abstract 
     Previous findings indicate that reducing brain insulin-like growth factor I receptor (IGF-IR) 
activity promotes ample neuroprotection. We now examined a possible action of IGF-IR on brain 
glucose transport to explain its wide protective activity, as energy availability is crucial for 
healthy tissue function. Using 18FGlucose PET we found that shRNA interference of IGF-IR in 
mouse somatosensory cortex significantly increased glucose uptake upon sensory stimulation. In 
vivo microscopy using astrocyte specific staining showed that after IGF-IR shRNA injection in 
somatosensory cortex, astrocytes displayed greater increases in glucose uptake as compared to 
astrocytes in the scramble-injected side. Further, mice with the IGF-IR knock down in astrocytes 
showed increased glucose uptake in somatosensory cortex upon sensory stimulation. Analysis of 
underlying mechanisms indicated that IGF-IR interacts with glucose transporter 1 (GLUT1), the 
main facilitative glucose transporter in astrocytes, through a mechanism involving interactions 
with the scaffolding protein GIPC and the multicargo transporter LRP1 to retain GLUT1 inside 
the cell. These findings identify IGF-IR as a key modulator of brain glucose metabolism through 
its inhibitory action on astrocytic GLUT1 activity. 
 
 
Introduction 
     Reduction of brain IGF-IR activity provides salutary effects. Intriguingly, neuroprotective 
actions of lowered brain IGF-IR encompass a wide variety of insults of different etiology (Biondi 
et al. 2015; Cohen et al. 2009; De Magalhaes Filho et al. 2016; Gontier et al. 2015), and even 
prolong lifespan (Kappeler et al., 2008). While diverse mechanisms have been invoked to 
explain the ample spectrum of beneficial actions of reduced IGF-IR activity (Gazit et al. 2016; 
Kenyon 2010; Lopez-Otin et al. 2013; Vilchez et al. 2014), it is possible that IGF-IR targets 
additional mechanisms of wide functional impact such as energy balance, as insulin-like 
receptors and their ligands are well known modulators of glucose and lipid handling in different 
tissues and species.     
     Conversely, IGF-I, the preferred ligand of IGF-IR, is generally considered a neuroprotective 
factor and has been proposed as a treatment for various neurodegenerative diseases (Fernandez 
and Torres-Aleman 2012) . This poses the paradox that either increasing IGF-I or reducing its 
receptor appears to lead to beneficial actions in the brain (Cohen and Dillin 2008; Fernandez and 
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Torres-Aleman 2012). While these apparently contradictory observations remain largely 
unexplained (but see (O'Neill et al., 2012), one possibility is that IGF-IR has ligand independent 
actions, as recently reported for apoptotic signaling through insulin receptor (IR) and IGF-IR 
(Boucher et al., 2010).   
     In the present work we analyzed a possible involvement of the IGF-I receptor on glucose 
handling by the brain, a key aspect in tissue homeostasis that could in theory form part of 
neuroprotection by insulin-like receptors, but remains little explored. We now describe that the 
IGF-I receptor inhibits in a ligand-independent manner the activity of glucose transporter 1 
(GLUT1) in astrocytes, adding further support for a broad beneficial effect of reducing brain 
IGF-IR levels.  
 
Materials and Methods 
Animals 
     Adult (3-5 months old) and neonatal C57BL6/J mice were used. Mutant mice with reduced 
levels of IGF-IR in astrocytes (AsIGF-IR +/- ) were obtained by crossing IGF-IRfloxP/floxP mice (the 
IGF-IR gene flanked by LoxP sites; Jackson Labs) with GFAP-Cre mice (Cre expression under 
the human GFAP promoter; Jackson Labs), both in a C57BlJ background. Littermates with IGF-
IRflox/flox, IGF-IR flox/-, and IGF-IR+/+ Cre+/? were pooled and used as controls. GFAP-Cre mice 
crossed with Rosa26 tomato-eGFP (a reporter mouse line from Jackson Labs) mice express GFP 
in astrocytes, whereas AsIGF-IR-/- mice expressed Cre in astrocytes (not shown). While levels of 
IGF-IR in the brain of AsIGF-IR -/- mice were significantly reduced (see below), levels of insulin 
receptor were normal (not shown). Animals were genotyped by PCR using primers for GFAP-
Cre forward: ACT CCT TCA TAA AGC CCT and reverse: ATC ACT CGT TGC ATC GAC 
CG, and for IGF-IR forward:  CTT CCC AGC TTG CTA CTC TAG G and reverse: CAG GCT 
TGC AAT GAG ACA TGG G. Two other transgenic mice lines (hGFAP-CreERT2 and 
IRloxP/loxP mice) were crossed to obtain GFAPIR-KO mice lacking IR in astrocytes when injected 
with tamoxifen, as explained in detail elsewhere (Garcia-Caceres et al. submitted). hGFAP-
CreERT2 mice, an inducible transgenic mouse line under the control of a GFAP promoter and 
estrogen (C57BL/6J background, FM Vaccarino, Yale University School of Medicine) were 
mated with IRloxP/loxP mice (generated by R Kahn, Joslin Diabetes Center), and breeding cages 
were maintained by mating IRloxP/loxP and IRloxP/loxP;hGFAP-CreERT2 mice. To excise loxP sites 
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by Cre recombination, 6 weeks-old male mice were administrated a daily tamoxifen injection (10 
mg/kg, intraperitoneal) for 5 days. Tamoxifen (Sigma) was dissolved in sunflower oil at a final 
concentration of 10 mg/ml at 37º, and then filter sterilized and stored for up to 7 days at 4ºC in 
the dark. IRloxP/loxP mice were used as controls and also were injected with tamoxifen. PCR 
genotyping was carried out using primer sets binding to Cre (Cre-1084, 5´- GCG GTC TGG 
CAG TAA AAA CTA TC-3´; Cre-1085, 5´- GTG AAA CAG CAT TGC TGT CAC TT-3´; Cre-
42, 5´-CTA GGC CAC AGA ATT GAA AGA TCT-3´; Cre-43, 5´-GTA GGT GGA AAT TCT 
AGC ATC ATC C-3 and crossing the loxP site (oKAHN03: 5- GAT GTG CAC CCC ATG TCT 
G-3´; oKAHN04: 5-TCT ATC AAC CGT GCC TAG AG-3´; oKAHN05: 5-CTG AAT AGC 
TGA GAC CAC AG-3´). Animal procedures followed European (86/609/EEC & 2003/65/EC, 
European Council Directives) guidelines and studies were approved by the respective local 
Bioethics Committees. All in vivo experiments were done blinded. 
Plasmid Constructions and viral packaging 
    For viral transduction we used a three-plasmid system previously described (Dull et al. 1998). 
The co-transfection system consisted of an shRNA plasmid against either IGF-IR or IR (also 
used for transfecting primary astrocyte cultures), a packaging construct (pCMV-dR8.2 Δvpr) and 
the vesicular stomatitis virus G-protein envelope (pMD2.G, Addgene, USA). shRNAs against 
Glut-1, IGF-IR, IR, scramble sequence and EGFP were from Origene (HuSH-29, Origene, 
USA): shRNA against GIPC was constructed as described in 
www.addgene.org/tools/protocols/plko/  using the primers: 5’CCGGACTCACCGA 
ACCTCGGAAGGCCTCGAGGCCTTCCGAGGTTCGGTGAGT TTTTTG3’ and 
5’AATTCAAAAAACTCACCGAACCTCGGAAGGCCTCGAGGCCTTCCGAGG 
TTCGGTGAGT3’ directed against the 684-704 fragment of GIPC mRNA. The transfer vector (5 
μg), the envelope (2 μg), and the packaging plasmids (5 μg) were co-transfected using calcium 
phosphate in human embryonic kidney 293 T cells (6 × 106 cells per dish) cultured in DMEM  
with 10% FCS and 1% penicillin/streptomycin. Lysosomal function was inhibited with 
cloroquine prior to transfection. The supernatant containing the viral particles was collected, 
filtered and stored at −80°C until use. Viral concentration was titrated as described (Munive et al. 
2016). Infection efficiency was ~80% as determined using GFP-expressing viral particles. 
shLRP-1 was obtained as described (Nishijima et al. 2010). GLUT1-Exo Flag was a kind gift of 
JC Rathmell (Wieman et al. 2007). 
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Cell cultures and transfections 
     Astroglial cultures with >95% GFAP-positive cells were prepared as described (Fernandez et 
al. 2007). Postnatal (day 3–4) brains from wild type, mutant As IGF-IR , and littermate mice 
were dissected and immersed in ice-cold Hank’s balance salt solution (HBSS, Life Technologies, 
Spain). Cortex and hippocampus were removed and mechanically dissociated. The resulting cell 
suspension was centrifuged and plated in DMEM/F-12 (Life Technologies) with 10% fetal 
bovine serum (Life Technologies) and 100 mg/ml of antibiotic-antimycotic solution (Sigma-
Aldrich). After 15–20 days, astrocytes were re-plated at 1.2×105 cells/well. For transfection, 
astrocytes were electroporated (2×106 astrocytes with 2 µg of plasmid DNA) before seeding 
using an astrocyte Nucleofector Kit (Amaxa, Lonza, Switzerland). After electroporation, cells 
were plated to obtain a final cell density on the day of the experiment similar to that obtained 
with the transfection method. The transfection efficiency was 60–80%, as assessed with a GFP 
vector. 
Glucose assays  
     We used 6-NBDG to measure glucose transport in astrocytes as shown by others (Barros et al. 
2009a). Briefly, cells well starved in serum free media for 3 hours. Then IGF-I (PreProTec, UK), 
insulin (Sigma, USA), or vehicle were added to a final concentration of 1nM. We then added 6-
NBDG (Setareh biotech, USA) to a final concentration of 30 µM. Cultures were kept for 3 hours 
at 37°C and then ice cold PBS was added and cells trypsinized. Cells were collected and FBS 
and PBS added. Fluorescence intensity was measured by flow cytometry (FACSAria cytometer, 
BD Biosciences, USA).  
In Situ Proximity Ligation Assays (PLA)  
     GLUT1 – IGF-IR interactions were detected in astrocytes grown on glass coverslips using the 
Duolink II in situ PLA detection Kit (OLink; Bioscience, Sweden) as previously described 
(Gonzalez et al. 2012). Astrocytes were fixed in 4% paraformaldehyde for 10 min, washed with 
PBS containing 20 mM glycine to quench the aldehyde groups, permeabilized with the same 
buffer containing 0.05% Triton X-100 for 5 min and successively washed with PBS. After 1 
h/37°C with the blocking solution in a pre-heated humidity chamber, astrocytes were incubated 
overnight with primary antibodies: rabbit polyclonal anti-GLUT1 antibody (1:100, ref. sc-7903; 
Santa Cruz Biotechnology) and monoclonal mouse anti-IGF-I receptor antibody (1:100, ref. sc-
463; Santra Cruz Biotechnology) and were processed following the instructions of the supplier 
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using the PLA probes detecting rabbit or mouse antibodies (Duolink II PLA probe anti-Rabbit 
plus and Duolink II PLA probe anti-Mouse minus diluted in antibody diluent to a concentration 
of 1:5) and a DAPI-containing mounting medium. Samples were observed in a Leica SP2 
confocal microscope (Leica Microsystems, Germany) equipped with an apochromatic 63X oil-
immersion objective. For images of each field a maximum projection (superimposed sections) in 
two channels (one per staining) of 6 to 12 Z stacks with a step size of 1 µm were acquired.  
Protein Translocation Assay 
     Translocation of GLUT1-Flag and IGF-IR to the cell membrane was evaluated following 
previously published procedures (Koshy et al. 2010). In brief, cultured astrocytes were labeled 
with anti IGF-IRα (SC-463, 1:50, Santa Cruz Biotechnology) or anti Flag M2 (F1804, 1:1000, 
Sigma-Aldrich) and secondary antibody Alexa Fluor 488 (A-11008, 1:1000, Life Technologies), 
and fixed before assessing fluorescence intensity by flow cytometry (FACS Aria, BD). 
Cell surface protein biotinylation 
    Cell surface proteins were biotinylated following the manufacturer´s instructions (EZ-
Link™Sulfo-NHS-SS-Biotin, Thermo Scientific). Biotinylated proteins were purified by affinity 
chromatography using NeutroAvidinAgarose Resin (Thermo Scientific) and resolved by Western 
blot. The membrane protein Na
+
/K
+ 
ATPase was used as a loading control. 
Quantitative PCR 
     Total RNA isolation from cell lysates or brain tissue was carried out with Trizol. One µg of 
RNA was reverse transcribed using High Capacity cDNA Reverse Transcription Kit (Life 
Technologies) according to the manufacturer’s instructions. For quantification of specific genes, 
total RNA was isolated and transcribed as above and 62.5 ng of cDNA was amplified using 
TaqMan probes for GLUT1, GluT4, IGF-IR or IR, and 18S as endogenous control (Life 
Technologies). Each sample was run in triplicate in 20 μl of reaction volume using TaqMan 
Universal PCR Master Mix according to the manufacturer’s instructions (Life Technologies). All 
reactions were performed in a 7500 Real Time PCR system (Life Technologies). Quantitative 
real time PCR analysis was carried out as described (Pfaffl 2001). Results were expressed as 
relative expression ratios on the basis of group means for target transcripts versus reference 18S 
transcript. At least three independent experiments were done. 
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Lentiviral particles administration 
     Mice were anesthetized by inhalation of a mixture of isofluorane/oxygen (5% induction, 2% 
maintenance). After removing the duramater, the tip of the glass pipette was placed onto the 
surface of the brain. Two µl of lentiviral shRNA against IGF-I receptor (∼4x1010 pfu/ml) were 
administered per mouse. Administration was made through a glass pipette connected to a 
Hamilton syringe. Rate of infusion was 1µl per 10 min. Stereotaxical coordinates were -1.06mm 
from bregma and -1mm lateral.  
In vivo astrocyte glucose uptake 
     Glucose uptake by astrocytes was evaluated as previously described by others (Chuquet et al., 
2010) according to the experimental set-up shown in Suppl Figure 1A, following procedures 
described in detail elsewhere (Perez-Alvarez et al. 2013). Astrocytes were labelled with 
sulforhodamine 101 (100 mg/kg, i.p. SR101; Sigma-Aldrich). Mice were anesthetized with 
urethane (1.7g/kg, i.p. Sigma-Aldrich) and their femoral artery cannulated. A 4 mm craniotomy 
around the area of interest was made. After 5 min, the cortex was washed and a drop of low 
melting point agarose (1% in HEPES-buffered solution. Sigma-Aldrich) and a 5 mm glass 
coverslip were placed carefully over the exposed cortex. Dental cement (Fortex, Facident, Spain) 
was applied to fix the coverslip. A light aluminum frame (2x3.5cm) with a central circular hole 
(10mm diameter) was attached to the skull centered on the craniotomy area and fixed with dental 
cement. The cranial frame was fixed to a heavy aluminum base. The base was moved to the 
imaging stage. The animals’ body temperature was monitored during the procedure using a rectal 
probe (Technomed Europe, The Netherlands) and regulated using a heating pad (RS Amidata, 
Spain) controlled by a thermostat (Cibertec, Spain) set at 37°C. 
6-NBDG administration 
     6-NBDG (Setareh biotech, USA) was dissolved in a solution of 55% of HEPES-ringed buffer 
and 45% of DMSO, pH 7.42, to a concentration of 5 mg/ml. A 300µl Hamilton syringe 
(Hamilton, USA) filled with the 6-NBDG solution was connected to the femoral artery cannula 
and placed in a micro-injector pump (Harvard Apparatus, USA). 6-NBDG was pumped at a rate 
of 20μl/min/100gr. 
Stimulation Paradigm 
     The whiskers of the animal’s snout were stimulated with 100 ms puffs of air produced at 5 Hz 
by a pressure injector (Dagan, USA) for 30 sec controlled by an Axon Digidata 1322A and 
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pClamp software (Molecular Devices, USA). Air was ejected at 1 bar pressure via capillary 
glass, attached to plastic tubing, positioned ~1 cm lateral and anterior to the animal’s nose to 
stimulate the whole left whisker pad. At the same time, tail pinching was performed at 2 Hz with 
steel forceps, providing a pairing protocol for astrocyte stimulation. 
Laser Scanning Confocal Microscopy (LSCM) 
     Imaging was performed with a custom-built confocal laser (CVI Melles Griot, UK) scanning 
microscope consisting of an Olympus FV300 laser scanning confocal system coupled to an 
Olympus BX61WI upright microscope (Olympus, Japan) and a Olympus LUMPLFL 60XW/IR 
water immersion objective (0.9NA; Olympus) 
Data analysis 
     Astrocytes were distinguished by using the red signal emitted by SR-101. Astrocytes 
concentrate SR-101, and their soma appear intensely bright (Nimmerjahn et al. 2004). Each 
image of the sequence was aligned over the previous image with Align Slice (ImageJ, National 
Institutes of Health, USA) to correct x–y deviation caused by possible drift of the tissue. 
Fluorescence intensity was measured in a region of interest (ROI) strictly limited to the somatic 
area. Signals were expressed as relative fluorescence changes (ΔF/F0), where F0 was the mean 
of the baseline period. Astrocytes showing variations greater than 1 were considered as 
responders. 
18F-FDG PET imaging 
     18F-FDG PET was used to measure brain glucose handling. Briefly, fasted mice were injected 
i.p. with the positron emitting radiotracer 18F-FDG (18.5 MBq in 0.2 ml of 0.9% NaCl, Instituto 
Tecnológico PET, Spain). During an uptake period of 45 min animals were anesthetized by 
inhalation of a mixture of isoflurane/oxygen (5% for induction and 2% for maintenance) and 
then placed on the bed of the tomograph. The duration of the PET acquisition was 20 min, 
immediately followed by a CT (computed tomography) scan. The scanner used was a specific 
small animal PET-CT hybrid tomograph (Albira ARS, Oncovision, Spain). After acquisition, 
PET images were reconstructed with an ordered subset expectation maximization (OSEM) 
algorithm, and with applied corrections for randoms, scatter, attenuation, dead time and radio 
element decay, whereas for the CT images a filtered back projection algorithm was used. For 
metabolic activity quantification, the procedure used was as follows: first, the CT image of the 
skull from each animal was co-registered to a magnetic resonance image (MRI) template of 
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mouse brain in which the regions of interest (ROIs) were previously delineated. After the CT 
image was co-registered, the spatial mathematic transformation was saved and then applied to its 
own fused PET image, allowing the correct matching between the PET image and the MRI 
template. Once the 18F-FDG uptake in the different brain regions was calculated (in kBq/cc 
units), the activity of each left hemisphere region was normalized to its homologous region in the 
right hemisphere and expressed as proportional uptake (left/right). All processes of visualization, 
co-registration and quantification were performed using PMOD 3.0 software (PMOD 
Technologies Ltd., Switzerland). 
Statistics 
     Normal distribution tests were carried out in all initial set of experiments and a non-
parametric Wilcoxon test was applied accordingly. For samples with normal distribution, 
parametric tests include one-way ANOVA followed by a Tukey HSD or t-test. A p<0.05 was 
considered significant. Results are shown as mean ± s.e.m. No statistical methods were used to 
predetermine sample sizes. Data collection and analysis were performed blinded to the 
conditions of the experiments only in in vivo experiments. There was no randomization of data 
collection or processing. 
 
Results 
IGF-IR in astrocytes modulates brain glucose uptake 
     We first examined whether IGF-IR affects brain glucose handling by reducing its levels with 
shRNA interference and measuring brain glucose uptake with 18F fluoro-2 deoxy-glucose micro-
PET imaging. A lentiviral vector expressing IGF-IR shRNA  (Suppl Figure 1A) was 
stereotaxically injected into one side of the somatosensory cortex of wild type mice, whereas the 
contralateral side was injected with scrambled shRNA (Suppl Figure 1B), using procedures 
already described in detail elsewhere (Carro et al. 2005). After measuring baseline levels, we 
stimulated the whiskers bilaterally to increase glucose flux into the somatosensory cortex. 
Whereas glucose uptake was increased in both sides after whisker stimulation (Suppl Figure 1C), 
normalization of glucose levels in the side injected with IGF-IR shRNA with those in the 
scramble-injected side, both under basal conditions and after stimulation of the whiskers, 
revealed a significantly greater increase in glucose uptake after stimulation (Figure 1). No 
changes in glucose uptake were seen in a brain area such as the caudate-putamen that is not 
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activated after whisker stimulation. Despite the limitations of PET analysis in small animals such 
as mice (Kuntner et al. 2009), these results indicate that reducing brain IGF-IR enhances brain 
glucose uptake in active brain regions. 
     Because it has been shown that astrocytes are the predominant type of cell involved in 
glucose uptake upon activation of the somatosensory cortex (Chuquet et al. 2010), we used in 
vivo fluorescence microscopy (Suppl Figure 2) to visualize astrocytes in mice injected with IGF-
IR shRNA in the somatosensory cortex, using procedures already described (Perez-Alvarez et al. 
2013). We found significantly larger increases after stimulation of the whiskers in glucose 
transport (detected with 6-NBDG) in somatosensory cortex astrocytes (identified with the 
astrocyte-specific fluorescent red marker SR101) injected with IGF-IR shRNA, as compared to 
scramble RNA-injected astrocytes (Figure 2B-D and supplementary video).  
     As injection of the lentiviral particles transducing IGF-IR shRNA in the brain affected all 
types of brain cells, we needed to confirm whether IGF-IR in astrocytes was involved in glucose 
uptake, Thus, we performed PET analysis in mice with reduced IGF-IR specifically in astrocytes 
(As IGF-IR+/-). Compared to littermates, a significant increase in glucose uptake in 
somatosensory cortex after sensory stimulation was seen in As IGF-IR+/- mice (Figure 2D). PET 
analysis was performed in heterozygous mice (As IGF-IR+/-) because homozygous mice (As 
IGF-IR-/-) have reduced brain size (not shown). Astrocytes from As IGF-IR+/- mice showed 
reduced responses to IGF-I (1 nM), as determined by phosphorylation of Akt (Suppl Figure 3A), 
even though total brain levels of IGF-IR were not significantly reduced in these mice, as many 
other brain cells express IGF-IR (Suppl Figure 3B).  
 
Opposing action of IR and IGF-IR on GLUT1 activity in astrocytes  
     We then examined mechanisms whereby IGF-IR reduces glucose transport using astrocyte 
cultures. We first confirmed that reduction of IGF-IR in shRNA IGF-IR-transfected astrocytes 
significantly increased glucose transport (Figure 3A). Because astrocytes also express IR (Suppl 
Figure 4A), we also tested its role on glucose transport. Intriguingly, reduction of IR levels 
(Suppl Figure 4B) decreased glucose transport in astrocytes (Figure 3A). Opposing actions of IR 
and IGF-IR on glucose transport were confirmed by the observation that when both receptors 
were reduced, the effects cancelled each other (Figure 3A). Modulation of basal glucose 
transport in astrocytes after reduction of either IR or IGF-IR reflects ligand-independent actions 
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of these receptors (Boucher et al. 2010), as experiments were conducted under serum-free 
conditions, and addition of either IGF-I or insulin in the presence or absence of the respective 
shRNAs did not alter glucose transport in any case (not shown).  
     Because GLUT1 is the main facilitative glucose transporter in astrocytes (Morgello et al. 
1995), we determined its role in IGF-IR and IR actions. We found that decreasing IR levels 
reduced GLUT1 mRNA (Figure 3B), resulting in decreased GLUT1 levels at the cell membrane 
(Figure 3C). Confirming these observations in vitro, we also found reduced levels of brain 
GLUT1 mRNA in mice lacking IR in astrocytes (GFAPIR-KO mice, Figure 3D). Indeed, 
GFAPIR-KO mice show wide disturbances in brain glucose handling, as reported elsewhere 
(Garcia-Caceres et al, in press). Thus, astrocytic IR modulates GLUT1 expression, and 
consequently GLUT1 protein levels at the cell membrane are also affected. On the other hand, 
reduction of IGF-IR by shRNA did not affect GLUT1 mRNA levels (Figure 3B), but resulted in 
increased amounts of GLUT1 at the cell membrane of astrocytes, as determined by flow 
cytometry and membrane protein biotinylation (Figure 3C,E). The latter suggests that IGF-IR 
retains GLUT1 inside the cell and agrees with the observation that reduction of IGF-IR levels 
increases glucose transport in astrocytes.  
     We then started to determine possible underlying mechanisms. IGF-IR associates with GIPC 
(GAIP-interacting protein, C terminus) (Booth et al. 2002; Bunn et al. 1999), a scaffolding 
protein that participates in protein trafficking and binds to many partners, including GLUT1 
(Bunn et al. 1999). We hypothesized that GIPC may simultaneously interact with IGF-IR and 
GLUT1 through its PDZ domain because GIPC can dimerize (Katoh, 2013). In support of this 
possibility we found that IGF-IR co-immunoprecipitates not only with GIPC, as already 
reported, but also with GLUT1, whereas GIPC, as expected, co-immunoprecipitates also with 
GLUT1 (Figure 4A). Proximity ligation assays (PLA) confirmed an interaction between IGF-IR 
and GLUT1 (Figure 4B). Significantly, neither GLUT1, or as previously shown (Ligensa et al. 
2001), nor GIPC, co-immunoprecipitate with the insulin receptor (Figure 4A). To further 
establish a role of GIPC in the interaction between IGF-IR and GLUT1 we reduced GIPC levels 
in astrocytes using GIPC shRNA (Suppl Figure 4C) and found that the interaction between IGF-
IR and GLUT1 was significantly reduced (Figure 4C).  
     We examined a potential intermediary role of lipoprotein-receptor associated protein 1 
(LRP1) in this mechanism as LRP1 is a multicargo membrane protein that associates to the IGF-I 
12 
 
receptor in other type of brain cells (Nishijima et al., 2010) and is involved in GLUT 
translocation in neurons (Liu et al. 2015). We confirmed that LRP1 and IGF-IR interact also in 
astrocytes (Suppl Figure 4D), and that LRP1 is required for IGF-IR to interact with GLUT1 and 
GIPC as its reduction with shRNA (Suppl Figure 4E) reduces the amount of IGF-IR that 
immunoprecipitates with GLUT1 and GIPC (Figure 4D). No direct interaction of LRP1 with 
GLUT1 was observed (Suppl Figure 4F). 
 
Discussion 
     The present observations indicate that IGF-IR regulates glucose transporter 1 activity in 
astrocytes, impacting in this way on overall brain glucose transport. When IGF-IR levels are 
reduced, GLUT1 locates at the cell membrane and transports glucose inside the cell. Thus, 
unbound GLUT1 may contribute to basal glucose transport in astrocytes. Conversely, when 
GLUT1 is bound to IGF-IR, it remains inside the cell and associates to IGF-IR through protein-
protein interactions involving GIPC and LRP1 (see Summary Graphic). As a facilitative glucose 
transporter, GLUT1 takes up extracellular glucose in a concentration-dependent manner, which 
explains increased glucose transport in shRNA IGF-IR-injected mice receiving sensory 
stimulation. Indeed, local blood flow is increased in response to enhanced neuronal activity (Roy 
and Sherrington 1890), and astrocytes, that fully wrap blood vessels (Mathiisen et al. 2010), will 
take up more glucose through GLUT1. In turn, previous observations indicate that activity-
dependent modulation of astrocytic glucose transport relies on stimulation of GLUT1 by 
glutamate via engagement of the Na+-glutamate co-transporter and intracellular Na+-Ca++ co-
signaling (Loaiza et al. 2003; Porras et al. 2008). Collectively, these observations provide 
additional information about the role of astrocytic GLUT1 in brain glucose metabolism.  
     In its IGF-IR-free state, GLUT1 is in the membrane and may be active. In this regard, and not 
withstanding different sensitivities of the methods used, the increase in glucose transport seen in 
astrocytes with reduced levels of IGF-IR is more robust that the increase seen in membrane 
GLUT1 levels. This could mean that the intrinsic activity of GLUT1, that can be regulated 
(Barnes et al. 2002), is also affected by IGF-IR. Thus, when associated to IGF-IR, GLUT1 is 
retained inside the cell and its activity is down-regulated. Bound and unbound GLUT1 may 
constitute two separate pools in astrocytes. We also speculate that when bound to IGF-IR, 
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GLUT1 may become subject to regulation by extracellular signals (glutamate…etc), but further 
work is needed.     
     This study confirms the utility of 6NBDG as a probe for glucose uptake, further supporting 
the notion that astrocytes are major contributors in glucose metabolism, as seen previously both 
in vivo (Chuquet et al. 2010), and in different in vitro preparations (Barros et al. 2009b; Jakoby 
et al. 2014). Importantly, both in anesthetized animals and in slices without anesthetics, 6NBDG 
showed preferential astrocytic uptake. Another important aspect confirmed by our findings is 
that IR and IGF-IR display ligand-independent activities that may, or may not, be related to the 
actions of their ligands (Boucher et al., 2010). In this regard, different authors have shown that 
IGF-I and insulin also affect glucose handling by astrocytes at different levels, including 
enhanced glucose uptake (Kum et al. 1992; Masters et al. 1991) and/or enhanced glycogen 
production (Dringen and Hamprecht 1992; Hamai et al. 1999; Muhic et al. 2015). These 
observations suggest that insulin peptides and their receptors form an intricate glucose regulatory 
network in astrocytes that may even act in apparently opposing manners. Indeed, and through 
entirely different mechanisms, IGF-IR exerts an intrinsic inhibitory action on astrocytic glucose 
transport, while IR displays an intrinsic stimulatory activity. In this way, glucose uptake in 
astrocytes may in part be determined by a balance between IGF-IR and IR levels. This suggests 
that physiological and pathological processes impacting on astrocytic insulin and IGF-I receptor 
levels will influence glucose transport by the brain in opposite directions. 
     Collectively, these observations would help reconcile the apparent controversy on the role of 
these receptors and their ligands in the brain (Cohen and Dillin 2008), which largely arises from 
studies in invertebrates harboring a single insulin-like receptor (Kenyon 2010). Thus, while in C 
elegans a single insulin-like receptor is modulated by many different ligands, even in an 
antagonistic fashion (Matsunaga et al. 2012), the acquisition of new insulin-like receptors in 
vertebrates has allowed the appearance of interactions among them. Based on present findings 
we consider that reported actions of insulin-like receptors in invertebrates should not be 
immediately inferred to be similar in vertebrates. The corollary of these observations is that 
invertebrate models of insulin-like receptor physiology in mammals should take into account the 
existence of two tyrosine kinase receptors, IGF-IR and IR, not present in invertebrates that may 
display cooperative (Boucher et al., 2010) or opposing activities (present observations), 
depending on biological context.  
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     Finally, since glucose transport by the brain deteriorates during aging and its associated 
pathologies (Mergenthaler et al. 2013), these observations provide further support for the use of 
strategies regulating brain IGF-IR levels to support healthy as well as pathological aging. Indeed, 
lowering IGF-IR in Alzheimer´s disease (AD) brains will not only diminish amyloidosis (Cohen 
et al. 2009), and related pathology  such as hippocampal hyperactivity (Gazit et al. 2016), but 
will also likely contribute to normalize glucose dysregulation present as a characteristic 
alteration of this disease (La Joie et al. 2012). Future work should examine major components of 
the IGF-IR pathway in astrocytes described herein for brain glucose regulation in experimental 
models of normal and pathological aging, as for example the recently described role of GLUT1 
in AD (Winkler et al. 2015). Altogether, these set of observations support  a role of an interaction 
between insulin and IGF-I receptors in modulating glucose handling by astrocytes, adding a new 
layer of regulation by astrocytes of brain energy economy (Allaman et al. 2011).  
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LEGENDS TO FIGURES 
 
Figure 1: IGF-IR inhibits brain glucose handling.  Adult mice were unilaterally injected with 
lentival particles expressing shRNA IGF-IR (n=5) in one side of the somatosensory cortex and 
with scramble shRNA-expressing viral particles in the contralateral side (see Suppl Fig 1B). 
After allowing 2 weeks of recovery, animals were submitted to PET scans, and after basal (white 
bars) measurements of 18F-FDG uptake they were bilaterally stimulated (black bars) +in their 
whiskers. Basal and stimulated responses in the shRNA IGF-IR injected site were normalized to 
responses in the scramble injected side. Significantly enhanced uptake in the somatosensory 
cortex injected with shRNA IGF-IR was seen in response to whisker stimulation. No changes 
were appreciated in a unstimulated area such as the caudate putamen, that was analyzed to 
determine region specificity in glucose responses to sensory stimulation (*p<0.05 vs basal). 
Lower panel: representative PET images under basal conditions and after whisker stimulation are 
shown. Greater signal (red) is seen after stimulation. 
 
Figure 2: IGF-IR inhibits astrocyte glucose transport in vivo. A, Representative 6-NBDG 
fluorescence traces of astrocytes of somatosensory cortex after scramble (left) or IGF-IR shRNA 
(right) injection in the somatosensory cortex. B, Representative confocal images of astrocytes 
(red, left image) accumulating 6NBDG (green, middle image) during whisker stimulation (see 
Suppl video for a full temporal sequence). Three astrocytes are indicated with arrowheads, two 
of them accumulate more 6-NBDG as shown in the merged image (right). Astrocytes were 
stained with the specific astrocyte dye SR101 administered by intraperitoneal injection whereas 
glucose transport was determined using the green fluorescent analog 6-NBDG delivered by intra-
femoral artery injection. C, Mice injected with IGF-IR shRNA  showed no changes in the 
number of responding astrocytes (left histograms) but displayed a great increase in glucose 
transport (measured as amplitude of the fluorescence response of 6-NBDG;  right  histograms, 
n= 139; ***p<0.001 vs scramble shRNA; n= 123). D, While baseline (white bars) brain glucose 
transport in somatosensory cortex of mice with knock down of IGF-IR in astrocytes (IGF-IR+/-) 
was similar to littermates, upon whisker stimulation significantly larger brain glucose transport 
was seen. (*p<0.05 vs basal and ##p<0.05 vs basal and vs stimulated littermates; n=6 per group). 
 
16 
 
Figure 3: Role of IGF-IR and IR on in vitro glucose transport by astrocytes. A, Depletion of 
IGF-IR in astrocytes by shRNA interference increases basal transport of 6-NBDG (n=6; 
***p<0.001 vs scramble-transfected astrocytes). Depletion of IR by shRNA interference elicits 
the opposite effect: a decrease in basal transport of 6-NBDG (n=6; ***p<0.001 vs scramble-
transfected astrocytes). Interference of both IR and IGF-IR in astrocytes results in abolition of 
the effects of each other and no changes in 6-NBDG transport (n=6). B, Depletion of IR, but not 
IGF-IR by shRNA interference decreases the amount of GLUT1 mRNA as determined by qPCR 
(n=3; ***p<0.001 vs scramble-transfected astrocytes). C, Reduction of IGF-IR increased the 
amount of GLUT1 in the cell membrane whereas depletion of IR decreased it (n=4; ***p<0.001, 
and *p<0.05 vs respective scramble). D, Brain levels of GLUT1 mRNA are significantly reduced 
in mice lacking insulin receptors in astrocytes (GFAPIR-KO), as compared to control littermates 
(**p<0.01 vs littermates; n=4). E, Increased cell surface levels of GLUT1 after transfection of 
astrocytes with shRNA for IGF-IR seen by flow cytometry (panel C), were confirmed by cell 
surface biotinylation assays. Cell membrane fraction was confirmed by the presence of the cell 
membrane protein Na+/K+ ATPase. 
 
Figure 4: Role of GLUT1 on IGF-IR effects on cultured astrocytes. A,  Analysis of 
interactions of IGF-IR with GLUT1 and GIPC using reciprocal immunoprecipitations and 
sequential blotting show that the 3 proteins interact with each other whereas only IGF-IR 
interacts with IR. Drawing: proposed interaction of GLUT1 with IGF-IR through GIPC. B, 
Proximity ligation assays (PLA) in astrocyte cultures show an interaction of IGF-IR with 
GLUT1 (red dots in left micrograph) that is absent when the IGF-IR antibody is omitted 
(Control). DAPI staining of astrocyte nuclei in blue. Bars are 20µm. C, Reduction of GIPC1 with 
shRNA interference resulted in significantly less IGF-IR bound to GLUT1. Representative blot 
and quantitation bars are shown (n=4; **p<0.01). D,  Reduction of LRP1 levels in astrocytes by 
shRNA reduces the interaction of GLUT1 and GIPC with IGF-IR.  
 
Summary Graphic: Schematic representation of IGF-IR/IR interactions with astrocytic 
GLUT1. When bound to IGF-IR, GLUT1 activity is reduced because IGF-IR retains it inside the 
cell through an interaction that involves the scaffolding protein GIPC and the transmembrane 
multicargo protein LRP1. When unbound, GLUT1 locates at the cell membrane, showing greater 
17 
 
sensitivity (illustrated as greater size) and glucose transport is increased. Thus, basal glucose 
transport by astrocytes will reflect the balance between IGF-IR-bound and –free GLUT1. In turn, 
IR favors the transcription of GLUT1 mRNA, resulting in increased levels of this transpoter at 
the cell membrane.  
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LEGENDS SUPPLEMENTARY FIGURES 
Supplementary Figure 1. A, Three different shRNAs for IGF-IR were tested in cultured 
astrocytes. Number 88 was selected based on its greater potency. B, Adult mice were injected 
with lentival particles expressing shRNA IGF-IR in one side of the somatosensory cortex and 
with scramble shRNA-expressing viral particles in the contralateral side. Lower micrograph: a 
representative GFP staining of GFP-expressing control viral vectors is shown to illustrate the 
spreading of viral expression within the somatosensory cortex (Scx). The circled area depicts the 
region selected for microscopy analysis. Bar is 500 µm. Hi: hippocampus; CC: corpus callosum. 
No spreading of virus was seen in the contralateral side. C, PET analysis of glucose uptake in the 
somatosensory cortex showed that basal glucose uptake was slightly, but not significantly 
reduced in the side injected with shRNA IGF-IR compared to the scramble-injected side. After 
whisker stimulation both sides showed increased uptake, but the increase over basal levels was 
greater in the shRNA IGF-IR side. D, Three different shRNAs for IR were tested in cultured 
astrocytes. Number 30 was selected for experimental use. 
 
Supplementary Figure 2. A, Time-line of experimental set-up for in vivo analysis of glucose 
transport by astrocytes. Animals received an ip injection of SR101 (100 mg/kg) immediately 
followed by ip urethane (1.7 g/kg). Once the animals were anesthesized, their femoral vein was 
cannulated and placed under the microscope. After a cranial window was opened and image 
stabilized, the animals were injected 6NBDG (see materials and methods for the detailed 
procedure) and recordings started. B,  Schematic illustration of the positioning of the microscope 
over the cranial window of an anesthesized mouse. C, Left: representative image of 
somatosensory cortex astrocytes labeled with SR101; right micrograph: uptake of 6NBDG in the 
somatosensory cortex under basal conditions. Bar is 20 µm. D, Representative measurements of 
three SR101-labeled astrocytes (1, 2, and 3 in left image) accumulating 6NBDG before (middle 
image), and after (right image) somatosensory stimulation. Fluorescence traces are shown in the 
rightmost panel. Bar is 10 µm.   
 
Supplementary Figure 3. A, In vitro responses to IGF-I (1 nM) in astrocytes derived from mice 
with knock down (AsIGF-IR+/- ) or knock out (AsIGF-IR-/-) IGF-I receptors in astrocytes were 
proportional to the reduction in IGF-IR levels, as measured by Akt phosphorylation (n=3; 
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*p<0.05 vs control and #p<0.05 vs IGF-I in control astrocytes). B, Brain levels of IGF-IR in 
mice with IGF-IR knock out in astrocytes (As IGF-IR-/-) were significantly reduced. Remaining 
IGF-IR is expressed by other brain cells. 
 
Supplementary Figure 4. A, Astrocytes express both insulin (IR) and IGF-I (IGF-IR) receptors 
as determined by qPCR (n=6). Levels are expressed relative to IR. B, Three different shRNAs 
for IR were tested in cultured astrocytes. Number 30 was selected for experimental use. C, 
shRNA GIPC reduces protein levels of GIPC in transfected astrocyte cultures. D,  LRP1 and 
IGF-IR co-immunoprecipitate in astrocyte lysates. Representative blot is shown. IP: IGF-IR. E, 
Transfection of astrocytes with shRNA against LRP1 reduces its levels in these cells. F, GIPC 
does not co-immunoprecipitate with LRP1 in astrocyte lysates. Representative blot.  
 
Video.  In response to whisker/tail stimulation, astrocytes (red) in somatosensory cortex increase 
glucose uptake (green). Stimulation is delivered at ∼9 sec in the video sequence. Astrocytes were 
stained with the specific astrocyte dye SR101 administered by intraperitoneal injection whereas 
glucose uptake was determined using the green fluorescent analog 6-NBDG delivered by intra-
femoral artery injection.  
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